Penn Pharma invests £3m in additional manufacturing capacity
Latest spend will meet customer demand for tablet manufacturing and coating capacity
Penn Pharma is to invest in additional specific tablet manufacturing and coating capacity to meet customer demand. The latest £3m spend is in addition to the £14m recently invested in a solid dose contained manufacturing facility to handle potent active pharmaceutical ingredients.
‘We are making this additional significant investment to meet our growing customer demands. It is fuelled by our demonstrated ability to provide pragmatic and timely solutions for their needs,’ said Penn Pharma Chief Executive Officer, Richard Yarwood. ‘At a time when many businesses are struggling we are continuing to grow the Penn business and our recent investments give us the platform to provide even better services to our customers.’
The new investment follows the recent completion of Penn Pharma’s new 15,000ft2 site for the clinical and commercial manufacture of tablets and capsules. The new industry-leading facility will deliver both the clinical and commercial contained manufacturing needs of its clients.
